colchicine

Taking Colchicine to Treat Gout

Indications, Dosages, and Common Side Effects

By Carol Eustice
Updated on August 03, 2024
Medically reviewed by Stella Bard, MD

Colchicine, a prescription medication available under the brand name Colcrys or in its generic form, represents a cornerstone in the management of gouty arthritis. This potent compound is uniquely derived from the dried seeds of Colchicum autumnale, commonly known as the autumn crocus or meadow saffron. Its long-standing efficacy in addressing the inflammatory aspects of gout has solidified its position as a preferred treatment option within clinical practice. Understanding the precise mechanisms, appropriate dosages, and potential considerations associated with colchicine use is crucial for effective patient care and optimal outcomes in mitigating the debilitating effects of gout.

Foot pain from gout.
Jan-Otto/E+/Getty Images

Indications for Using Colchicine

The historical use of C. autumnale alkaloids for the treatment of gout spans centuries, with its medicinal value first documented in the first century A.D. and its specific application for gout dating back to 1810. While predominantly recognized for its role in gout management, colchicine's therapeutic utility extends beyond this condition, offering benefits in a range of other inflammatory disorders. Its ability to modulate inflammatory processes makes it a versatile agent for various conditions, underscoring its broad pharmaceutical relevance.

One such condition where colchicine proves beneficial is amyloidosis2, a rare group of diseases marked by the abnormal buildup of amyloid proteins in various organs, leading to organ dysfunction. Colchicine helps by reducing the inflammatory response associated with certain types of amyloidosis, thus potentially slowing disease progression and alleviating symptoms. Similarly, in Behcet's disease3, a chronic inflammatory disorder affecting multiple body systems, colchicine is utilized to manage the recurrent painful oral and genital ulcers, as well as the skin lesions and joint pain characteristic of the condition. Its anti-inflammatory properties contribute to reducing the frequency and severity of these inflammatory manifestations.

Colchicine is also indicated for dermatitis herpetiformis4, a chronic, intensely itchy skin condition characterized by bumps and blisters. Though primarily treated with dietary changes to manage gluten sensitivity, colchicine can be used as an adjunct therapy to reduce inflammation and alleviate the severe itching and rash. For familial Mediterranean fever (FMF)5, a genetic inflammatory disorder causing recurrent episodes of fever and inflammation, colchicine is the cornerstone of treatment, effectively preventing acute attacks and reducing the risk of amyloidosis, a serious complication.

In Paget's disease of bone6, a chronic disorder that causes bones to grow abnormally large and weak, colchicine has been explored for its anti-inflammatory effects to potentially manage associated pain, although it's not a primary treatment for the bone remodeling process itself. Furthermore, colchicine is an established therapy for pericarditis7, inflammation of the sac-like membrane surrounding the heart (pericardium). It helps reduce inflammation and recurrent episodes of chest pain, making it a valuable addition to treatment protocols for both acute and recurrent forms of this condition.

Finally, pseudogout8, a condition similar to gout but caused by calcium pyrophosphate crystals rather than uric acid, also benefits from colchicine. While not the primary cause of pseudogout, the drug's anti-inflammatory action can help mitigate the acute pain and swelling during flares, providing relief and supporting recovery. These diverse applications highlight colchicine's multifaceted role in managing a range of inflammatory and crystal-induced arthropathies, extending its utility well beyond gout alone.

Mechanism of Action

While colchicine possesses potent anti-inflammatory properties, it's important to note that its efficacy is specifically limited to inflammatory pain, particularly that associated with gout. Colchicine is not classified as an analgesic and therefore does not directly alleviate general pain. Crucially, it also does not influence or alter high uric acid levels, which are the root cause of gout attacks9. Its mechanism of action is distinct and focused on modifying the body's inflammatory response to the presence of uric acid crystals.

The primary way colchicine works is by precisely binding to a specific type of white blood cell known as a neutrophil. Neutrophils are a key component of the immune system, acting as first responders to inflammation and infection. In the context of gout, when uric acid crystals accumulate in a joint, they trigger an acute inflammatory cascade, drawing neutrophils to the affected area. These cells then engulf the crystals, releasing inflammatory mediators that lead to the intense pain, swelling, and redness characteristic of a gout flare.

By binding to neutrophils, colchicine effectively impairs their ability to migrate to sites where uric acid crystals have aggregated. This crucial action prevents the neutrophils from initiating the inflammatory response that typically follows crystal deposition. By tempering this inflammatory cascade, colchicine significantly reduces the associated pain and discomfort experienced during an acute gout attack. This suppressive effect on neutrophil function is pivotal, as it helps to decrease the severity and duration of acute gout attacks, thereby offering substantial relief to patients.

Dosages

Colchicine therapy for gout is typically initiated in patients experiencing two or more gout attacks per year. The standard starting dose for prophylaxis (prevention) is generally two 0.6 mg colchicine tablets daily. This daily regimen continues while the patient concurrently undergoes uric acid-lowering therapy, usually with medications like Uloric (febuxostat) or allopurinol. The combined therapy is maintained until the patient's serum uric acid level consistently falls below the target of 6.0 mg/dL, indicating effective control of uric acid.

For acute gout flares, the dosage of colchicine may be temporarily increased to three tablets a day for a few days to rapidly address the inflammatory response. However, close monitoring is essential during this increased dosage. If the patient experiences significant gastrointestinal (GI) discomfort, such as nausea, vomiting, or diarrhea, the daily dose may need to be promptly decreased to one tablet daily to improve tolerability. It is critical that the drug be stopped entirely if gastrointestinal discomfort or diarrhea becomes severe, as these symptoms can indicate a systemic reaction to the medication and could lead to dehydration or electrolyte imbalances.

Gout Prevention

Colchicine is also strongly recommended for regular use between acute gout attacks, serving as a vital component of prophylactic (preventive) therapy. This consistent use aims to reduce the frequency and intensity of future flares, thereby significantly improving a patient's quality of life and preventing joint damage over time. The appropriate dosage for prevention depends on the frequency of a patient's gout attacks.

For individuals who experience less than one gout attack per year, the usual prophylactic dose is 0.5 or 0.6 mg, administered three or four days per week. This intermittent dosing helps maintain a protective level of the medication without unnecessary continuous exposure. Conversely, for those who experience more than one gout attack annually, a daily dose of 0.5 or 0.6 mg is typically prescribed to provide more consistent anti-inflammatory support. In more severe or frequently recurring cases, a physician may deem it necessary to prescribe two or three 0.5 mg or 0.6 mg tablets daily, carefully balancing efficacy with potential side effects9.

While colchicine is primarily reserved for use in adults experiencing acute gout flares and for long-term prevention, its use in younger populations is more restricted. It can be used prophylactically in adolescents aged 16 and over when indicated for gout prevention. However, its only approved use in children under 16 is specifically for the treatment of familial Mediterranean fever (FMF), highlighting its targeted application in pediatric inflammatory conditions where its benefits are clearly established and outweigh potential risks.

Side Effects

Patients taking colchicine should be aware that adverse reactions can occur, and it is crucial to monitor for their potential manifestation. One of the more serious potential long-term adverse effects associated with prolonged colchicine therapy is bone marrow depression. This condition can lead to several severe blood disorders, including aplastic anemia (a deficiency of all types of blood cells), agranulocytosis (a severe reduction in the number of white blood cells called granulocytes, increasing infection risk), or thrombocytopenia (a deficiency of platelets, leading to increased bleeding risk). These are serious complications that necessitate immediate medical attention10.

Beyond these rare but severe hematologic effects, other possible adverse reactions have been reported with colchicine use. These can include peripheral neuritis, which involves inflammation of nerves outside the brain and spinal cord, leading to pain, numbness, or weakness in the extremities. Purpura, characterized by purple-colored spots on the skin caused by small bleeds under the skin, may also occur. Myopathy11, a disease of the muscle that can cause muscle weakness, pain, and cramps, is another potential concern, and patients should report any new or worsening muscle symptoms.

Additionally, patients may experience hair loss, which, while often reversible, can be distressing. Reversible azoospermia12, a condition characterized by the complete absence of sperm in semen, has also been linked to colchicine use, particularly relevant for male patients considering fertility. Common and more frequently encountered side effects associated with colchicine therapy include vomiting, diarrhea, and nausea. These gastrointestinal symptoms are particularly prevalent when higher, maximum doses are prescribed. To help mitigate these common GI side effects and improve patient tolerability, colchicine may be taken with food, which can help buffer the stomach and reduce direct irritation10.

Considerations and Contraindications for Taking Colchicine

The use of colchicine during pregnancy requires careful consideration, as pregnant women must weigh the potential risks against the anticipated benefits. Colchicine has the capacity to arrest cell division, which means it carries a significant potential risk to a developing fetus. Therefore, colchicine should be administered during pregnancy only if the potential benefit to the mother unequivocally justifies the potential risk to the fetus, a decision made in close consultation with a healthcare provider. Similar caution should be exercised when colchicine is administered to a woman who is nursing, as the drug may pass into breast milk and potentially affect the infant13.

Gout Doctor Discussion Guide

Get our printable guide for your next doctor's appointment to help you ask the right questions.
Download PDF
Sign up for our Health Tip of the Day newsletter, and receive daily tips that will help you live your healthiest life.
Email Address
Sign Up
You're in!
Thank you, , for signing up.
There was an error. Please try again.

Beyond pregnancy and nursing, there are specific situations where colchicine use is contraindicated due to the risk of serious adverse effects. Colchicine should not be used by individuals with a known hypersensitivity or allergic reaction to the drug, as this could trigger a severe immune response. Furthermore, it is contraindicated in patients with severe underlying gastrointestinal, renal (kidney), hepatic (liver), or cardiac (heart) disorders. These conditions can impair the body's ability to process and eliminate colchicine, leading to toxic accumulation and exacerbating existing organ dysfunction.

For instance, in individuals with compromised kidney or liver function, the drug can accumulate to dangerous levels, increasing the risk of severe side effects. Similarly, severe cardiac or gastrointestinal issues can be worsened by colchicine's systemic effects or its direct impact on these systems. Additionally, individuals with pre-existing blood disorders, such as those that might predispose them to bone marrow suppression, should strictly avoid colchicine, given its potential to induce aplastic anemia, agranulocytosis, or thrombocytopenia. These contraindications underscore the importance of a thorough medical evaluation before initiating colchicine therapy to ensure patient safety and optimize treatment outcomes10.

Read more:

13 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Colchicine.
  2. Unverdi S, Inal S, Ceri M, et al. Is colchicine therapy effective in all patients with secondary amyloidosis?. Ren Fail. 2013;35(8):1071-4. doi:10.3109/0886022X.2013.811345
  3. Nair JR, Moots RJ. Behcet's disease. Clin Med (Lond). 2017;17(1):71-77. doi:10.7861/clinmedicine.17-1-71
  4. Silvers DN, Juhlin EA, Berczeller PH, Mcsorley J. Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol.
  5. Sönmez HE, Batu ED, Özen S. Familial Mediterranean fever: current perspectives. J Inflamm Res. 2016;9:13-20. doi:10.2147/JIR.S91352
  6. Theodors A, Askari AD, Wieland RG. Colchicine in the treatment of Paget disease of bone: a new therapeutic approach. Clin Ther.
  7. Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014;(8):CD010652. doi:10.1002/14651858.CD010652.pub2.
  8. Macmullan P, Mccarthy G. Treatment and management of pseudogout: insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):121-31. doi:10.1177/1759720X11432559
  9. Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment Options for Gout. Dtsch Arztebl Int. 2017;114(13):215-222. doi:10.3238/arztebl.2017.0215
  10. Sadiq NM, Robinson KJ, Terrell JM. Colchicine. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
  11. Altiparmak MR, Pamuk ON, Pamuk GE, Hamuryudan V, Ataman R, Serdengecti K. Colchicine neuromyopathy: a report of six cases. Clin Exp Rheumatol.
  12. Ding J, Shang X, Zhang Z, et al. FDA-approved medications that impair human spermatogenesis. Oncotarget. 2017;8(6):10714-10725. doi:10.18632/oncotarget.12956
  13. Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(2):382-387. doi:10.1093/rheumatology/kex353

Additional Reading

By Carol Eustice Carol Eustice is a writer covering arthritis and chronic illness, who herself has been diagnosed with both rheumatoid arthritis and osteoarthritis.